Обзор рекомендаций American College of Rheumatology / Vasculitis Foundation по лечению системных васкулитов крупных сосудов (гигантоклеточного артериита и артериита Такаясу)

Обсуждаются основные положения рекомендаций Американской коллегии ревматологов (American College of Rheumatology) и Фонда васкулитов (Vasculitis Foundation) по лечению пациентов с системными васкулитами крупных сосудов, которые были опубликованы в августе 2021 г. В результате подробного рассмотрения современных данных группой экспертов были предложены 22 рекомендации и 2 дополнения для гигантоклеточного артериита (ГКА), а также 20 рекомендаций и 1 дополнение для артериита Такаясу (АТ), на основании которых представлены алгоритмы лечения пациентов с данными заболеваниями. Зафиксировано расширение значения генно-инженерной биологической терапии, в первую очередь тоцилизумаба при ГКА и ингибиторов фактора некроза опухоли альфа при АТ. Новые рекомендации не должны рассматриваться как окончательные стандарты, но призваны стать основанием для выбора персонифицированной стратегии лечения больных с васкулитами крупных сосудов и послужить отправной точкой для дальнейших исследований.

1. Maz M, Chung SA, Abril A, Langford CA, Gorelik M, Guyatt G, et al. 2021 American College of Rheumatology/Vasculitis Foundation guideline for the management of giant cell arteritis and Takayasu arteritis. Arthritis Rheumatol. 2021;73(8):1349-1365. doi: 10.1002/art.41774

2. Chung SA, Gorelik M, Langford CA, Maz M, Abril A, Guyatt G, et al. 2021 American College of Rheumatology/Vasculitis Foundation guideline for the management of polyarteritis nodosa. Arthritis Rheumatol. 2021;73(8):1384-1393. doi: 10.1002/art.41776

3. Chung SA, Langford CA, Maz M, Abril A, Gorelik M, Guyatt G, et al. 2021 American College of Rheumatology/Vasculitis Foundation guideline for the management of antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheumatol. 2021;73(8):1366-1383. doi: 10.1002/art.41773

4. Бекетова ТВ, Попов ИЮ, Бабак ВВ. Обзор рекомендаций по лечению АНЦА-ассоциированных системных васкулитов, представленных в 2021 г. Американской коллегией ревматологов и Фондом васкулитов. Научно-практическая ревматология. 2021;59(6):684-692. doi: 10.47360/1995-4484-2021-684-692

5. Mahr A, Saba M, Kambouchner M, Polivka M, Baudrimont M, Brochériou I, et al. Temporal artery biopsy for diagnosing giant cell arteritis: the longer, the better? Ann Rheum Dis. 2006;65(6):826-828. doi: 10.1136/ard.2005.042770

6. Durling B, Toren A, Patel V, Gilberg S, Weis E, Jordan D. Incidence of discordant temporal artery biopsy in the diagnosis of giant cell arteritis. Can J Ophthalmol. 2014;49(2):157-161. doi: 10.1016/j.jcjo.2013.12.008

7. Dejaco C, Singh YP, Perel P, Hutchings A, Camellino D, Mackie S, et al.; European League Against Rheumatism; American College of Rheumatology. 2015 recommendations for the management of polymyalgia rheumatica: A European League Against Rheumatism/American College of Rheumatology collaborative initiative. Arthritis Rheumatol. 2015;67(10):2569-2580. doi: 10.1002/art.39333

8. Achkar AA, Lie JT, Hunder GG, O’Fallon WM, Gabriel SE. How does previous corticosteroid treatment affect the biopsy findings in giant cell (temporal) arteritis? Ann Intern Med. 1994;120(12):987-992. doi: 10.7326/0003-4819-120-12199406150-00003

9. Bury D, Joseph J, Dawson TP. Does preoperative steroid treatment affect the histology in giant cell (cranial) arteritis? J Clin Pathol. 2012;65:1138-1140. doi: 10.1136/jclinpath-2012-200870

10. Le K, Bools LM, Lynn AB, Clancy TV, Hooks WB 3rd, Hope WW. The effect of temporal artery biopsy on the treatment of temporal arteritis. Am J Surg. 2015;209(2):338-341. doi: 10.1016/j.amjsurg.2014.07.007

11. Ray-Chaudhuri N, Kiné DA, Tijani SO, Parums DV, Cartlidge N, Strong NP, et al. Effect of prior steroid treatment on temporal artery biopsy findings in giant cell arteritis. Br J Ophthalmol. 2002;86(5):530-532. doi: 10.1136/bjo.86.5.530

12. Dejaco C, Ramiro S, Duftner C, Besson FL, Bley TA, Blockmans D, et al. EULAR recommendations for the use of imaging in large vessel vasculitis in clinical practice. Ann Rheum Dis. 2018;77(5):636-643. doi: 10.1136/annrheumdis-2017-212649

13. Pfadenhauer K, Weinerth J, Hrdina C. Vertebral arteries: А target for FDG-PET imaging in giant cell arteritis? Clinical, ultrasonographic and PET study in 46 patients. Nuklearmedizin. 2011; 50:28-32. doi: 10.3413/nukmed-0335-10-07

14. Quinn KA, Ahlman MA, Malayeri AA, Marko J, Civelek AC, Rosenblum JS, et al. Comparison of magnetic resonance angiography and 18F-fluorodeoxyglucose positron emission tomography in large-vessel vasculitis. Ann Rheum Dis. 2018;77(8):1165-1171. doi: 10.1136/annrheumdis-2018-213102

15. Lee KH, Cho A, Choi YJ, Lee SW, Ha YJ, Jung SJ, et al. The role of (18) F-fluorodeoxyglucose-positron emission tomography in the assessment of disease activity in patients with Takayasu arteritis. Arthritis Rheum. 2012;64(3):866-875. doi: 10.1002/art.33413

16. Walter MA, Melzer RA, Schindler C, Müller-Brand J, Tyndall A, Nitzsche EU. The value of [18F]FDG-PET in the diagnosis of large-vessel vasculitis and the assessment of activity and extent of disease. Eur J Nucl Med Mol Imaging. 2005;32(6):674-681. doi: 10.1007/s00259-004-1757-9

17. Grayson PC, Alehashemi S, Bagheri AA, Civelek AC, Cupps TR, Kaplan MJ, et al. 18 F-fluorodeoxyglucose-positron emission tomography as an imaging biomarker in a prospective, longitudinal cohort of patients with large vessel vasculitis. Arthritis Rheumatol. 2018;70(3):439-449. doi: 10.1002/art.40379

18. Grayson PC, Tomasson G, Cuthbertson D, Carette S, Hoffman GS, Khalidi NA, et al.; Vasculitis Clinical Research Consortium. Association of vascular physical examination findings and arteriographic lesions in large vessel vasculitis. J Rheumatol. 2012;39(2):303-309. doi: 10.3899/jrheum.110652

19. Stone JH, Tuckwell K, Dimonaco S, Klearman M, Aringer M, Blockmans D, et al. Trial of tocilizumab in giant-cell arteritis. N Engl J Med. 2017;377(4):317-328. doi: 10.1056/NEJMoa1613849

20. Mahr AD, Jover JA, Spiera RF, Hernández-García C, Fernández-Gutiérrez B, Lavalley MP, et al. Adjunctive methotrexate for treatment of giant cell arteritis: An individual patient data meta-analysis. Arthritis Rheum. 2007;56(8):2789-2797. doi: 10.1002/art.22754

21. Hoffman GS, Cid MC, Hellmann DB, Guillevin L, Stone JH, Schousboe J, et al.; International Network for the Study of Systemic Vasculitides. A multicenter, randomized, doubleblind, placebo-controlled trial of adjuvant methotrexate treatment for giant cell arteritis. Arthritis Rheum. 2002;46(5):1309-1318. doi: 10.1002/art.10262

22. Villiger PM, Adler S, Kuchen S, Wermelinger F, Dan D, Fiege V, et al. Tocilizumab for induction and maintenance of remission in giant cell arteritis: A phase 2, randomised, double-blind, placebo-controlled trial. Lancet. 2016;387(10031):1921-1927. doi: 10.1016/S0140-6736(16)00560-2

23. Langford CA, Cuthbertson D, Ytterberg SR, Khalidi N, Monach PA, Carette S, et al.; Vasculitis Clinical Research Consortium. A randomized, double-blind trial of abatacept (CTLA-4Ig) for the treatment of giant cell arteritis. Arthritis Rheumatol. 2017;69(4):837-845. doi: 10.1002/art.40044

24. Seror R, Baron G, Hachulla E, Debandt M, Larroche C, Puéchal X, et al. Adalimumab for steroid sparing in patients with giant-cell arteritis: Results of a multicentre randomised controlled trial. Ann Rheum Dis. 2014;73(12):2074-2081. doi: 10.1136/annrheumdis-2013-203586

25. Aeschlimann FA, Eng SWM, Sheikh S, Laxer RM, Hebert D, Noone D, et al. Childhood Takayasu arteritis: Disease course and response to therapy. Arthritis Res Ther. 2017;19(1):255. doi: 10.1186/s13075-017-1452-4

26. Mekinian A, Comarmond C, Resche-Rigon M, Mirault T, Kahn JE, Lambert M, et al.; French Takayasu Network. Efficacy of biological-targeted treatments in Takayasu arteritis: Multicenter, retrospective study of 49 patients. Circulation. 2015;132(18):16931700. doi: 10.1161/CIRCULATIONAHA.114.014321

27. Schmidt J, Kermani TA, Bacani AK, Crowson CS, Matteson EL, Warrington KJ. Tumor necrosis factor inhibitors in patients with Takayasu arteritis: Experience from a referral center with long-term follow-up. Arthritis Care Res (Hoboken). 2012;64(7):1079-1083. doi: 10.1002/acr.21636

28. Nakaoka Y, Isobe M, Takei S, Tanaka Y, Ishii T, Yokota S, et al. Efficacy and safety of tocilizumab in patients with refractory Takayasu arteritis: Results from a randomised, double-blind, placebo-controlled, phase 3 trial in Japan (the TAKT study). Ann Rheum Dis. 2018;77(3):348-354. doi: 10.1136/annrheumdis-2017-211878

29. Mekinian A, Resche-Rigon M, Comarmond C, Soriano A, Constans J, Alric L, et al.; French Takayasu Network. Efficacy of tocilizumab in Takayasu arteritis: Multicenter retrospective study of 46 patients. J Autoimmun. 2018;91:55-60. doi: 10.1016/j.jaut.2018.04.002

30. Chevalet P, Barrier JH, Pottier P, Magadur-Joly G, Pottier MA, Hamidou M, et al. A randomized, multicenter, controlled trial using intravenous pulses of methylprednisolone in the initial treatment of simple forms of giant cell arteritis: A one year followup study of 164 patients. J Rheumatol. 2000;27(6):1484-1491.

31. Mazlumzadeh M, Hunder GG, Easley KA, Calamia KT, Matteson EL, Griffing WL, et al. Treatment of giant cell arteritis using induction therapy with high-dose glucocorticoids: A doubleblind, placebo-controlled, randomized prospective clinical trial. Arthritis Rheum. 2006;54(10):3310-3318. doi: 10.1002/art.22163

32. Mutoh T, Shirai T, Fujii H, Ishii T, Harigae H. Insufficient use of corticosteroids without immunosuppressants results in higher relapse rates in Takayasu arteritis. J Rheumatol. 2020;47(2):255263. doi: 10.3899/jrheum.181219

33. Comarmond C, Biard L, Lambert M, Mekinian A, Ferfar Y, Kahn JE, et al.; French Takayasu Network. Long-term outcomes and prognostic factors of complications in Takayasu arteritis: A multicenter study of 318 patients. Circulation. 2017;136(12):1114-1122. doi: 10.1161/CIRCULATIONAHA.116.027094

34. Gülcü A, Gezer NS, Akar S, Akkoç N, Önen F, Göktay AY. Long-term follow-up of endovascular repair in the management of arterial stenosis caused by Takayasu’s arteritis. Ann Vasc Surg. 2017;42:93-100. doi: 10.1016/j.avsg.2016.10.066

35. García-Martínez A, Hernández-Rodríguez J, Grau JM, Cid MC. Treatment with statins does not exhibit a clinically relevant corticosteroid-sparing effect in patients with giant cell arteritis. Arthritis Rheum. 2004;51:674-678. doi: 10.1002/art.20541

36. Pugnet G, Sailler L, Fournier JP, Bourrel R, Montastruc JL, Lapeyre-Mestre M. Predictors of cardiovascular hospitalization in giant cell arteritis: Effect of statin exposure. A French population-based study. J Rheumatol. 2016;43(12):2162-2170. doi: 10.3899/jrheum.151500

37. de Souza AW, Machado NP, Pereira VM, Arraes AE, Reis Neto ET, Mariz HA, et al. Antiplatelet therapy for the prevention of arterial ischemic events in Takayasu arteritis. Circ J. 2010;74(6):1236-1241. doi: 10.1253/circj.cj-09-0905

38. Berger CT, Wolbers M, Meyer P, Daikeler T, Hess C. High incidence of severe ischaemic complications in patients with giant cell arteritis irrespective of platelet count and size, and platelet inhibition. Rheumatology (Oxford). 2009;48(3):258-261. doi: 10.1093/rheumatology/ken480

39. Narváez J, Bernad B, Gómez-Vaquero C, García-Gómez C, Roig-Vilaseca D, Juanola X, et al. Impact of antiplatelet therapy in the development of severe ischemic complications and in the outcome of patients with giant cell arteritis. Clin Exp Rheumatol. 2008;26(3 Suppl 49):S57-S62.

40. Nesher G, Berkun Y, Mates M, Baras M, Rubinow A, Sonnenblick M. Low-dose aspirin and prevention of cranial ischemic complications in giant cell arteritis. Arthritis Rheum. 2004;50(4):1332-1337. doi: 10.1002/art.20171

41. Both M, Aries PM, Müller-Hülsbeck S, Jahnke T, Schäfer PJ, Gross WL, et al. Balloon angioplasty of arteries of the upper extremities in patients with extracranial giant-cell arteritis. Ann Rheum Dis. 2006;65(9):1124-1130. doi: 10.1136/ard.2005.048470

42. Clifford AH, Arafat A, Idrees JJ, Roselli EE, Tan CD, Rodriguez ER, et al. Outcomes among 196 patients with noninfectious proximal aortitis. Arthritis Rheumatol. 2019;71(12):2112-2120. doi: 10.1002/art.40855

43. Mennander AA, Miller DV, Liang KP, Warrington KJ, Connolly HM, Schaff HV, et al. Surgical management of ascending aortic aneurysm due to non-infectious aortitis. Scand Cardiovasc J. 2008;42(6):417-424. doi: 10.1080/14017430802023086

44. Kinjo H, Kafa A. The results of treatment in renal artery stenosis due to Takayasu disease: Comparison between surgery, angioplasty, and stenting. A monocentrique retrospective study. G Chir. 2015;36:161-167. doi: 10.11138/gchir/2015.36.4.161

45. Park MC, Lee SW, Park YB, Lee SK, Choi D, Shim WH. Postinterventional immunosuppressive treatment and vascular restenosis in Takayasu’s arteritis. Rheumatology (Oxford). 2006;45:600-605. doi: 10.1093/rheumatology/kei245

46. Wang X, Dang A, Lv N, Cheng N, Cheng X, Yang Y, et al. Longterm outcomes of coronary artery bypass grafting versus percutaneous coronary intervention for Takayasu arteritis patients with coronary artery involvement. Semin Arthritis Rheum. 2017;47:247-252. doi: 10.1016/j.semarthrit.2017.03.009

47. Labarca C, Makol A, Crowson CS, Kermani TA, Matteson EL, Warrington KJ. Retrospective comparison of open versus endovascular procedures for Takayasu arteritis. J Rheumatol. 2016;43(2):427-432. doi: 10.3899/jrheum.150447

48. Khalilullah M, Tyagi S. Percutaneous transluminal angioplasty in Takayasu arteritis. Heart Vessels Suppl. 1992;7:146-153. doi: 10.1007/BF01744561

49. Sharma S, Gupta H, Saxena A, Kothari SS, Taneja K, Guleria S, et al. Results of renal angioplasty in nonspecific aortoarteritis (Takayasu disease). J Vasc Interv Radiol. 1998;9(3):429-435. doi: 10.1016/s1051-0443(98)70294-5

50. Sun Y, Ma L, Ma L, Kong X, Chen H, Lv P, et al. Cyclophosphamide could be a better choice than methotrexate as induction treatment for patients with more severe Takayasu’s arteritis. Rheumatol Int. 2017;37(12):2019-2026. doi: 10.1007/s00296-017-3847-6

51. Zheng T, Zhu S, Ou JF, Fang WG, Qiao ZY, Qi RD, et al. Treatment with corticosteroid and/or immunosuppressive agents before surgery can effectively improve the surgical outcome in patients with Takayasu’s arteritis. J Invest Surg. 2019;32(3): 220-227. doi: 10.1080/08941939.2017.1408718

52. Fields CE, Bower TC, Cooper LT, Hoskin T, Noel AA, Panneton JM, et al. Takayasu’s arteritis: Operative results and influence of disease activity. J Vasc Surg. 2006;43(1):64-71. doi: 10.1016/j.jvs.2005.10.010

53. Ham SW, Kumar SR, Wang BR, Rowe VL, Weaver FA. Late outcomes of endovascular and open revascularization for nonatherosclerotic renal artery disease. Arch Surg. 2010;145(9):832-839. doi: 10.1001/archsurg.2010.183